|
US7105574B1
(en)
|
1999-03-26 |
2006-09-12 |
Vical Incorporated |
Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
|
|
US6936464B1
(en)
|
1992-10-02 |
2005-08-30 |
Cancer Research Technology Limited |
Immune responses to fusion proteins
|
|
GB9506466D0
(en)
*
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
WO1996006938A1
(de)
*
|
1994-08-26 |
1996-03-07 |
Hoechst Aktiengesellschaft |
Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
|
|
US6911216B1
(en)
|
1994-10-12 |
2005-06-28 |
Genzyme Corporation |
Targeted delivery via biodegradable polymers
|
|
ES2264136T3
(es)
*
|
1995-02-21 |
2006-12-16 |
Cantab Pharmaceuticals Research Limited |
Preparaciones virales, vectores, inmunogenos y sus vacunas.
|
|
US5824485A
(en)
*
|
1995-04-24 |
1998-10-20 |
Chromaxome Corporation |
Methods for generating and screening novel metabolic pathways
|
|
US6265387B1
(en)
*
|
1995-10-11 |
2001-07-24 |
Mirus, Inc. |
Process of delivering naked DNA into a hepatocyte via bile duct
|
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
|
US7507722B1
(en)
*
|
1999-11-05 |
2009-03-24 |
Roche Madison Inc. |
Intravascular delivery of nucleic acid
|
|
US6365344B1
(en)
|
1996-01-23 |
2002-04-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for screening for transdominant effector peptides and RNA molecules
|
|
EP0877752B1
(de)
|
1996-01-23 |
2003-05-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
|
|
US5783431A
(en)
*
|
1996-04-24 |
1998-07-21 |
Chromaxome Corporation |
Methods for generating and screening novel metabolic pathways
|
|
US6242211B1
(en)
|
1996-04-24 |
2001-06-05 |
Terragen Discovery, Inc. |
Methods for generating and screening novel metabolic pathways
|
|
EP0803573A1
(de)
*
|
1996-04-25 |
1997-10-29 |
Gesellschaft für Biotechnologische Forschung mbH (GBF) |
Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe
|
|
EP0805207A1
(de)
*
|
1996-05-02 |
1997-11-05 |
Gesellschaft für Biotechnologische Forschung mbH (GBF) |
Polycistronische Expressionsplasmid für Tumorabstossungen
|
|
US20060002949A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
|
JP2001512973A
(ja)
*
|
1997-02-24 |
2001-08-28 |
ヘキスト・マリオン・ルセル・インコーポレイテッド |
β−アミロイドのプロセシングの改良されたアッセイ
|
|
EP1019082B2
(de)
|
1997-10-02 |
2008-06-04 |
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. |
Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
|
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
|
JP2001523480A
(ja)
*
|
1997-11-20 |
2001-11-27 |
バイカル インコーポレイテッド |
サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
|
|
FR2772047B1
(fr)
*
|
1997-12-05 |
2004-04-09 |
Ct Nat D Etudes Veterinaires E |
Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
|
|
US20030118567A1
(en)
*
|
1999-03-26 |
2003-06-26 |
Stewart Duncan John |
Cell-based therapy for the pulmonary system
|
|
US9585916B2
(en)
|
1999-03-26 |
2017-03-07 |
Northern Therapeutics Inc. |
Cell based therapy for the pulmonary system
|
|
CA2266805C
(en)
|
1998-03-27 |
2015-04-28 |
An-Go-Gen Inc. |
Cell-based gene therapy in the treatment of pulmonary disorders
|
|
US6482406B1
(en)
|
1999-03-26 |
2002-11-19 |
Duncan J. Stewart |
Cell-based gene therapy for the pulmonary system
|
|
US6592623B1
(en)
|
1999-08-31 |
2003-07-15 |
Virginia Commonwealth University Intellectual Property Foundation |
Engineered muscle
|
|
DE60012711T2
(de)
*
|
1999-03-26 |
2005-08-18 |
Vical, Inc., San Diego |
Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
|
|
WO2000061184A2
(en)
*
|
1999-04-08 |
2000-10-19 |
Glenn Gregory M |
Dry formulation for transcutaneous immunization
|
|
US6696424B1
(en)
|
1999-05-28 |
2004-02-24 |
Vical Incorporated |
Cytofectin dimers and methods of use thereof
|
|
US6943152B1
(en)
*
|
1999-06-10 |
2005-09-13 |
Merial |
DNA vaccine-PCV
|
|
US6541458B1
(en)
*
|
1999-07-16 |
2003-04-01 |
Merial |
Feline calicivirus genes and vaccines in particular recombinant vaccines
|
|
ES2269199T3
(es)
*
|
1999-11-05 |
2007-04-01 |
Mirus Bio Corporation |
Suministro intravascular de acido nucleico.
|
|
ES2170622B1
(es)
*
|
1999-12-03 |
2004-05-16 |
Consejo Superior De Investigaciones Cientificas |
Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
|
|
AU1954001A
(en)
*
|
1999-12-10 |
2001-06-18 |
Ariad Gene Therapeutics, Inc. |
Methods for high level expression of genes in primates
|
|
US7078388B2
(en)
*
|
2000-01-21 |
2006-07-18 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
|
US6852705B2
(en)
|
2000-01-21 |
2005-02-08 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP1278551A2
(de)
*
|
2000-04-21 |
2003-01-29 |
Vical Incorporated |
Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
|
|
US6645745B1
(en)
|
2000-05-30 |
2003-11-11 |
Epidauros Biotechnologie Ag |
Identification of a new member of the cytochrome P450 3A (CYP3A) gene family: CYP3AX
|
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
DE60143959D1
(de)
|
2000-08-25 |
2011-03-10 |
Basf Plant Science Gmbh |
En kodieren
|
|
WO2002018546A2
(en)
|
2000-09-01 |
2002-03-07 |
Virginia Commonwealth University Intellectual Property Foundation |
Plasma-derived-fibrin-based matrices and tissue
|
|
EP1366077B1
(de)
|
2000-09-15 |
2011-05-25 |
Coley Pharmaceutical GmbH |
Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
|
|
US20030074679A1
(en)
*
|
2000-12-12 |
2003-04-17 |
Schwartz Robert J. |
Administration of nucleic acid sequence to female animal to enhance growth in offspring
|
|
WO2002059142A2
(en)
|
2001-01-26 |
2002-08-01 |
Epidauros Biotechnologies Ag |
Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications
|
|
EP1372708B1
(de)
|
2001-02-13 |
2008-06-18 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY |
Impstoffe zur transkutanen immunisierung gegen reisediarrhö
|
|
AT410634B
(de)
|
2001-02-21 |
2003-06-25 |
Franz X Dr Heinz |
Attenuierte lebendimpfstoffe
|
|
WO2003015716A2
(en)
*
|
2001-08-13 |
2003-02-27 |
Ige Therapeutics, Inc. |
Immunoglobulin e vaccines and methods of use thereof
|
|
US20030109037A1
(en)
*
|
2001-09-24 |
2003-06-12 |
Reid Christopher Brian |
Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
|
|
US20080206202A1
(en)
*
|
2001-09-24 |
2008-08-28 |
Christopher Reid |
Methods for application of endogenous or exogenous stem/progenitor or their progeny for treatment of disease
|
|
US20030157641A1
(en)
*
|
2001-11-16 |
2003-08-21 |
Idec Pharmaceuticals Corporation |
Polycistronic expression of antibodies
|
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
|
ATE459880T1
(de)
|
2002-04-17 |
2010-03-15 |
Deutsches Krebsforsch |
Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade.
|
|
SI1496944T1
(sl)
*
|
2002-05-01 |
2009-02-28 |
Univ Florida |
Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
|
|
US20060093589A1
(en)
*
|
2004-02-19 |
2006-05-04 |
Warrington Kenneth H |
Vp2-modified raav vector compositions and uses therefor
|
|
CA2542171C
(en)
|
2002-06-26 |
2015-12-15 |
Abbott Gmbh & Co. Kg |
Modulators and modulation of the interaction between rgm and neogenin
|
|
US6809191B2
(en)
*
|
2002-07-03 |
2004-10-26 |
Vaxim, Inc. |
GM-CSF nucleic acid sequences
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
AU2003302724A1
(en)
*
|
2002-08-13 |
2004-07-09 |
Mcivor, Scott, R. |
Methods of using vectors to treat metabolic disorders
|
|
AU2003260426A1
(en)
|
2002-08-16 |
2004-03-11 |
Glycotope Gmbh |
Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
|
|
WO2004018512A2
(en)
|
2002-08-23 |
2004-03-04 |
Epidauros Biotechnologie Ag |
Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
|
|
WO2004032713A2
(en)
*
|
2002-10-04 |
2004-04-22 |
Nanomatrix, Inc. |
Sealants for skin and other tissues
|
|
WO2004060346A2
(en)
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
US20040136960A1
(en)
*
|
2003-01-10 |
2004-07-15 |
Wolff Jon A. |
Devices and processes for distribution of genetic material to mammalian limb
|
|
AU2004257373B2
(en)
|
2003-07-16 |
2011-03-24 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
DK1654353T3
(da)
|
2003-08-18 |
2013-08-26 |
Glycotope Gmbh |
Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
|
|
ATE466106T1
(de)
|
2003-10-10 |
2010-05-15 |
Deutsches Krebsforsch |
Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
|
|
US8076459B2
(en)
|
2003-10-16 |
2011-12-13 |
Micromet Ag |
Multispecfic deimmunized CD3-binders
|
|
US7700737B2
(en)
|
2003-12-05 |
2010-04-20 |
Multimmune Gmbh |
Therapeutic and diagnostic anti-Hsp70 antibodies
|
|
CN1989244B
(zh)
|
2004-02-09 |
2013-04-03 |
柏格丹由里 |
用于治疗cns病症的tgf-r信号传递抑制剂
|
|
US7504243B2
(en)
|
2004-03-19 |
2009-03-17 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods for the production of biliverdin
|
|
CA2568201C
(en)
|
2004-05-24 |
2013-07-30 |
Universitat Zu Koln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
|
EP1602926A1
(de)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
|
|
CN101094688B
(zh)
|
2004-09-13 |
2013-05-01 |
建新公司 |
多聚构建体
|
|
AU2005287557B2
(en)
|
2004-09-21 |
2011-10-13 |
Biontech Ag |
Use of microproteins as tryptase inhibitors
|
|
WO2006113209A1
(en)
|
2005-04-15 |
2006-10-26 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
|
|
US8048446B2
(en)
*
|
2005-05-10 |
2011-11-01 |
Drexel University |
Electrospun blends of natural and synthetic polymer fibers as tissue engineering scaffolds
|
|
AU2006249144B2
(en)
|
2005-05-18 |
2011-11-17 |
Ablynx Nv |
Improved NanobodiesTM against Tumor Necrosis Factor-alpha
|
|
LT2444424T
(lt)
|
2005-05-20 |
2018-10-25 |
Ablynx N.V. |
Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
US20090068158A1
(en)
*
|
2005-12-09 |
2009-03-12 |
Medin Jeffrey A |
Thymidylate kinase mutants and uses thereof
|
|
CA2566267A1
(en)
*
|
2005-12-09 |
2007-06-09 |
University Health Network |
Thymidylate kinase mutants and uses thereof
|
|
NZ569204A
(en)
|
2005-12-21 |
2012-03-30 |
Micromet Ag |
Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
|
|
EP2514824A3
(de)
|
2006-03-03 |
2013-01-23 |
Amorfix Life Sciences Ltd. |
Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen
|
|
CA2655990A1
(en)
|
2006-06-22 |
2007-12-27 |
Tai June Yoo |
Restoration of hearing loss
|
|
WO2008028686A2
(en)
|
2006-09-10 |
2008-03-13 |
Glycotope Gmbh |
Use of human cells of myeloid leukaemia origin for expression of antibodies
|
|
PL1920781T3
(pl)
|
2006-11-10 |
2015-06-30 |
Glycotope Gmbh |
Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
|
|
US9156914B2
(en)
|
2006-12-19 |
2015-10-13 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
|
AU2007336242B2
(en)
|
2006-12-19 |
2012-08-30 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
WO2008086556A1
(en)
|
2007-01-16 |
2008-07-24 |
The University Of Queensland |
Method of inducing an immune response
|
|
CN106890342B
(zh)
|
2007-02-06 |
2022-09-23 |
俞泰俊 |
使用基因疗法治疗和预防神经变性疾病
|
|
CA2584494A1
(en)
*
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
|
WO2008119565A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific binding domain
|
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
WO2008124768A1
(en)
|
2007-04-09 |
2008-10-16 |
The General Hospital Corporation |
Hemojuvelin fusion proteins and uses thereof
|
|
UA100692C2
(ru)
|
2007-05-02 |
2013-01-25 |
Мериал Лимитед |
Днк-плазмиды, имеющие повышенную экспрессию и стабильность
|
|
EP2208737B1
(de)
|
2007-05-03 |
2017-07-05 |
Lysomab GmbH |
Komplementierte Faktor-H-abgeleitete Kurzkonsenswiederholung-Antikörperkonstrukte
|
|
US8765462B2
(en)
|
2007-05-04 |
2014-07-01 |
University Health Network |
IL-12 immunotherapy for cancer
|
|
WO2008148057A2
(en)
|
2007-05-23 |
2008-12-04 |
Vical Incorporated |
Cationic lipids compositions and methods for enhancing immune responses to vaccines
|
|
US20110217274A1
(en)
|
2007-05-29 |
2011-09-08 |
Reld Christopher B |
Methods for production and uses of multipotent ,pluripotent, differentiated and disease-resistant cell populations
|
|
WO2009095517A2
(es)
|
2008-01-29 |
2009-08-06 |
Proyecto De Biomedicina Cima, S.L. |
Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
WO2009114942A1
(en)
*
|
2008-03-20 |
2009-09-24 |
University Health Network |
Thymidylate kinase fusions and uses thereof
|
|
US8557965B2
(en)
|
2008-04-07 |
2013-10-15 |
Ablynx N.V. |
Single variable domains against notch pathway members
|
|
US9694055B2
(en)
|
2008-05-09 |
2017-07-04 |
Wake Forest University Health Sciences |
Renal tissue regeneration
|
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
MX2011003502A
(es)
|
2008-10-01 |
2011-09-01 |
Micromet Ag |
Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
|
|
JP5832293B2
(ja)
|
2008-12-04 |
2015-12-16 |
オプコ ファーマシューティカルズ、エルエルシー |
血管新生促進vegfイソ型を選択的に抑制する組成物および方法
|
|
PT2414322T
(pt)
|
2009-03-20 |
2022-12-07 |
Egen Inc |
Derivados de poliamina
|
|
MX2011010681A
(es)
|
2009-04-10 |
2012-01-20 |
Ablynx Nv |
Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
|
|
CN102459332B
(zh)
|
2009-06-05 |
2015-08-19 |
埃博灵克斯股份有限公司 |
用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
|
|
CA2770075C
(en)
*
|
2009-08-07 |
2021-08-24 |
Perrine Martin |
Composition for treating hbv infection
|
|
EP2501414B1
(de)
|
2009-11-17 |
2018-01-10 |
The Trustees Of The University Of Pennsylvania |
Smn-delta-7-degron: neuartige zusammensetzungen und verfahren zu ihrer verwendung
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
PH12012501070A1
(en)
|
2009-12-08 |
2017-08-23 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
|
AU2011269260B2
(en)
|
2010-06-23 |
2015-01-15 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechtes |
Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
|
|
ES2657705T3
(es)
|
2010-06-23 |
2018-03-06 |
Deutsches Krebsforschungszentrum |
Secuencias de virus TT específicas y moléculas de ADN quiméricas de células hospedadoras de virus TT para uso en el diagnóstico, prevención y tratamiento del cáncer y la autoinmunidad
|
|
EP2481801A1
(de)
|
2011-01-28 |
2012-08-01 |
Deutsches Krebsforschungszentrum |
Inhibitoren von verzweigtkettiger Aminotransferase-1 (BCAT1) zur Behandlung von Neoplasie
|
|
US8951736B2
(en)
|
2011-04-29 |
2015-02-10 |
Sequenom, Inc. |
Multimer glycosylated nucleic acid binding protein conjugates and uses thereof
|
|
DK2532747T3
(en)
|
2011-06-09 |
2016-01-25 |
Deutsches Krebsforsch |
Modulators of glycerol-3-phosphate dehydrogenase (GPD2) in therapy
|
|
US20140120106A1
(en)
|
2011-07-06 |
2014-05-01 |
Yale University |
Stimulation of Arterial Collateral Growth and Lymphogenesis
|
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
|
EP2748302B1
(de)
|
2011-08-22 |
2018-08-15 |
Glycotope GmbH |
Mikroorganismen mit einem tumor-antigen
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
WO2013113615A1
(en)
|
2012-02-03 |
2013-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
|
|
DK2657340T3
(en)
|
2012-04-25 |
2017-02-27 |
Deutsches Krebsforsch |
Thioredoxin-interacting protein (TXNIP) inhibitors for therapy
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
US10028998B2
(en)
|
2012-10-30 |
2018-07-24 |
Suppremol Gmbh |
Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
|
|
ES2778033T3
(es)
|
2012-11-16 |
2020-08-07 |
Poseida Therapeutics Inc |
Enzimas específicas de sitio y métodos de uso
|
|
WO2014145205A2
(en)
|
2013-03-15 |
2014-09-18 |
St. Jude Children's Research Hospital |
Methods and compositions of p27kip1 transcription modulators
|
|
EP2808338B1
(de)
|
2013-09-16 |
2016-03-30 |
CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Mutiertes Calreticulin zur Diagnose von Myeloidmalignitäten
|
|
CA2925281C
(en)
|
2013-09-25 |
2022-05-03 |
Zoetis Services Llc |
Pcv2b divergent vaccine composition and methods of use
|
|
EP2868751A1
(de)
|
2013-10-30 |
2015-05-06 |
Deutsches Krebsforschungszentrum |
HCBI-Sequenzen als früher Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des zentralen Nervensystems, und als Ziel zur Behandlung und Prävention von Krebs
|
|
EP2937096B1
(de)
|
2014-04-23 |
2019-08-21 |
Julius-Maximilians-Universität Würzburg |
Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern
|
|
EP3143143A1
(de)
|
2014-05-15 |
2017-03-22 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antagonisten von slc38a9 und deren verwendung in der therapie
|
|
EP2966176A1
(de)
|
2014-07-10 |
2016-01-13 |
Deutsches Krebsforschungszentrum |
HCBIO-, MSBI-, MSSI- und CMI-Sequenzen als frühe Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des ZNS und als Ziel zur Behandlung und Prävention dieser Erkrankungen
|
|
EP3262064A1
(de)
|
2015-02-23 |
2018-01-03 |
Seagull Therapeutics SAS |
Nichtnatürliche semaphorine 3 und deren medizinische verwendung
|
|
JP2018521689A
(ja)
|
2015-06-17 |
2018-08-09 |
ポセイダ セラピューティクス, インコーポレイテッド |
タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
|
|
CN108137595B
(zh)
|
2015-06-18 |
2021-04-20 |
听治疗有限责任公司 |
预防和治疗听力损失的方法和组合物
|
|
JP7065772B2
(ja)
|
2015-12-22 |
2022-05-12 |
エクスエル‐プロテイン ゲーエムベーハー |
低反復性ヌクレオチド配列を有する、プロリンおよびアラニン残基が豊富な反復性アミノ酸配列をコードする核酸
|
|
EP3216458A1
(de)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
|
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
|
EP3478722A1
(de)
|
2016-06-30 |
2019-05-08 |
F. Hoffmann-La Roche AG |
Verbesserte adoptive t-zelltherapie
|
|
CA3056837A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
SG11201908784TA
(en)
|
2017-03-27 |
2019-10-30 |
Hoffmann La Roche |
Improved antigen binding receptor formats
|
|
EP3609519B1
(de)
|
2017-04-11 |
2025-11-26 |
University of Maryland, Baltimore |
Zusammensetzungen und verfahren zur behandlung von entzündungen und krebs
|
|
WO2019126578A1
(en)
|
2017-12-20 |
2019-06-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
|
EP3794042B1
(de)
|
2018-05-18 |
2024-03-27 |
Daiichi Sankyo Co., Ltd. |
Conjugue agent cytotoxique et anticorps anti-muc1-exatecan
|
|
EP3686289A1
(de)
|
2019-01-24 |
2020-07-29 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Cmi-sequenzen als frühmarker für die zukünftige entwicklung von krebs, atherosklerose, diabetes und erkrankungen des zns und als ziel für die behandlung und prävention dieser erkrankungen
|
|
WO2022029051A1
(en)
|
2020-08-03 |
2022-02-10 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
AR124562A1
(es)
|
2020-10-28 |
2023-04-12 |
Hoffmann La Roche |
Receptores de unión al antígeno mejorada
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
US20250325469A1
(en)
|
2021-01-24 |
2025-10-23 |
Michael David FORREST |
Inhibitors of atp synthase - cosmetic and therapeutic uses
|
|
JP2024528631A
(ja)
|
2021-07-22 |
2024-07-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
ヘテロ二量体Fcドメイン抗体
|
|
CA3237616A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
JP2025512797A
(ja)
|
2022-03-25 |
2025-04-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
改善されたキメラ受容体
|
|
AR129560A1
(es)
|
2022-06-08 |
2024-09-04 |
Tidal Therapeutics Inc |
Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
|
|
JP7880106B2
(ja)
|
2022-08-09 |
2026-06-25 |
湖南長星生物医藥有限公司 |
金属-ポリフェノール複合体粒子、薬物-脂質粒子、並びにその製造方法及び応用
|
|
IL318505A
(en)
|
2022-08-09 |
2025-03-01 |
Hunan Lonstar Biotech Co Ltd |
Metal-phospholipid complex, metal-phospholipid complex particle, drug-lipid particle, method for preparing same, and use thereof
|
|
TWI872406B
(zh)
*
|
2022-12-07 |
2025-02-11 |
日商都滾筒工業股份有限公司 |
有孔搬送輥、片材製造裝置及片材加工裝置
|
|
WO2026030375A2
(en)
|
2024-07-30 |
2026-02-05 |
Genzyme Corporation |
Lipid nanoparticles and methods of manufacture and use thereof
|
|
WO2026072557A2
(en)
|
2024-09-24 |
2026-04-02 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
WO2026112559A1
(en)
|
2024-11-25 |
2026-05-28 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|